Saturday, 31 October 2026European Markets

VALUE8 CUM PREF, SOGN SPAREBANK, Another 1 Companies Have A High Dividend Yield And Return On Equity In The Financial Services Sector.

Loading stream...

(VIANEWS) - VALUE8 CUM PREF (PREVA.AS) is among this list of stock assets with the highest dividend rate and return on equity on the Financial Services sector.

Financial Asset Price Forward Dividend Yield Return on Equity
VALUE8 CUM PREF (PREVA.AS) €5.05 7.09% 6.16%
SOGN SPAREBANK (SOGN.OL) kr218.90 6.52% 8.5%
VALUE8 (VALUE.AS) €5.80 3.13% 12.74%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. VALUE8 CUM PREF (PREVA.AS)

7.09% Forward Dividend Yield and 6.16% Return On Equity

Value8 N.V. is a private equity firm specializing in middle market, buyout, add-on and growth capital investments in small and medium-sized companies. The firm primarily invests in the food, healthcare, business and financial services, energy, safety and security, water and environment, leisure, luxury products and internet sectors. It typically invests in Western Europe, primarily in the Netherlands, Belgium and France. The firm considers investments in companies with an enterprise value between €10 million ($10.74 million) and €150 million ($208.87 million). The firm prefers to take a seat on the board of directors and seeks to exit the investment through a public listing. Value8 NV was founded in 2008 and is headquartered in Bussum, Netherlands.

Earnings Per Share

As for profitability, VALUE8 CUM PREF has a trailing twelve months EPS of €1.87.

PE Ratio

VALUE8 CUM PREF has a trailing twelve months price to earnings ratio of 2.7. Meaning, the purchaser of the share is investing €2.7 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.16%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 1091.9%, now sitting on 8.05M for the twelve trailing months.

Yearly Top and Bottom Value

VALUE8 CUM PREF's stock is valued at €5.05 at 22:30 EST, under its 52-week high of €5.20 and way higher than its 52-week low of €4.32.

Volume

Today's last reported volume for VALUE8 CUM PREF is 136 which is 64.3% below its average volume of 381.

Moving Average

VALUE8 CUM PREF's value is above its 50-day moving average of €4.90 and higher than its 200-day moving average of €4.84.

More news about VALUE8 CUM PREF.

2. SOGN SPAREBANK (SOGN.OL)

6.52% Forward Dividend Yield and 8.5% Return On Equity

Sogn Sparebank provides various banking products and services in Norway. The company offers saving and pension accounts; home loans and small loans, as well as loans for cars and other vehicles; credit and other cards; and mobile and online banking services, as well as payment services. It also provides bank guarantees, construction loans, overdraft, and business loans, as well as leasing and refinancing without collateral. In addition, the company offers home and leisure, animals, damage, car, Death, critical illness, disabled, work machine, data attack, property damage, health, homeowners, agriculture, craftsman, commercial vehicle, business, and personnel insurance products. Sogn Sparebank was founded in 1846 and is based in Årdalstangen, Norway.

Earnings Per Share

As for profitability, SOGN SPAREBANK has a trailing twelve months EPS of kr31.92.

PE Ratio

SOGN SPAREBANK has a trailing twelve months price to earnings ratio of 6.86. Meaning, the purchaser of the share is investing kr6.86 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.5%.

Volume

Today's last reported volume for SOGN SPAREBANK is 628 which is 41.12% above its average volume of 445.

More news about SOGN SPAREBANK.

3. VALUE8 (VALUE.AS)

3.13% Forward Dividend Yield and 12.74% Return On Equity

Value8 N.V. is a private equity firm specializing in middle market, buyout, add-on and growth capital investments in small and medium-sized companies. The firm primarily invests in the food, healthcare, business and financial services, energy, safety and security, water and environment, leisure, luxury products and internet sectors. It typically invests in Western Europe, primarily in the Netherlands, Belgium and France. The firm considers investments in companies with an enterprise value between €10 million ($10.74 million) and €150 million ($208.87 million). The firm prefers to take a seat on the board of directors and seeks to exit the investment through a public listing. Value8 NV was founded in 2008 and is headquartered in Bussum, Netherlands.

Earnings Per Share

As for profitability, VALUE8 has a trailing twelve months EPS of €1.28.

PE Ratio

VALUE8 has a trailing twelve months price to earnings ratio of 4.53. Meaning, the purchaser of the share is investing €4.53 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.74%.

Volume

Today's last reported volume for VALUE8 is 2109 which is 34.82% below its average volume of 3236.

Revenue Growth

Year-on-year quarterly revenue growth grew by 229.7%, now sitting on 15M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, VALUE8's stock is considered to be oversold (<=20).

More news about VALUE8.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com